Iron containing phosphate binder and iron metabolism
Phase 4
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-jRCTs051190013
- Lead Sponsor
- Kuragano Takahiro
- Brief Summary
The results suggested that the avoid aimlessly administration of iron containing phosphate binder could maintain target P, Ca, and PTH levels without iron overload and Hb overshot.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Maintenance hemodialysis patient with high serum phosphate level.
Exclusion Criteria
1) Patients who received maintenance hemodialysis for < 6month.
2) Patients with severe heart failure (>NYHA III), respiratory failure, malignancy disease, or severe liver dysfunction.
3) Patient with high serum ferritin level(>100 ng/mL) at the start of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events (cerebral cardiovascular disease, infection, hospitalization) and survival.
- Secondary Outcome Measures
Name Time Method The effect of iron containing phosphate binder on the anemia (Hb, Ret, RDW,dose of iron and ESA), iron metabolism(ferritin, TSAT, hepcidin, NTBI), CKD-MBD(Ca, P, FGF23,dose of phosphate binder, vitaminD, cinacalcet), arteriosclerosis (PWV, ABI, TMAO, LVMI), and microbiome.